A Phase 3 interventional study of Imidazolyl ethanamide pentandioic acid and placebo in Common Cold and Influenza, sponsored by Valenta Pharm JSC. Completed at 13 sites in Russian Federation. Open to participants aged 3 Years to 6 Years. Per ClinicalTrials.gov, last updated 2016-06-09.
Sponsored by Valenta Pharm JSC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Common Cold with a site in Russian Federation — 1 open to participants now, 1 under way, none of them phase 3. Common Cold · Russian Federation.
Among the 13 studies in Common Cold with a site in Russian Federation, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2016, is one of 8 in phase 3, and was the 3rd registered.
219 studies on the registry are indexed under Common Cold; 23 are open to participants now.
Browse Common Cold studies →1 of the 13 studies in Common Cold with a site in Russian Federation is open now. Recruiting first, the newest first:
Valenta Pharm JSC · Sites in Russian Federation
Ages 13–17
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 14 Common Cold studies recruiting now, 4 (29%) set no upper age limit and 9 (64%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 3 Years to 6 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 190 is above the median of 150 across 184 interventional studies indexed under Common Cold.
Median enrollment 250 across the 11 interventional studies, 140 across the 2 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 13 have an industry lead sponsor. The 4 most frequent:
Valenta Pharm JSC is the lead sponsor of 40 studies on the registry; 18 are open to participants now.
Valenta Pharm JSC has 9 studies filed under Common Cold — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Common Cold with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether Ingavirin ® dosed 30 mg daily is effective and safe in the treatment of influenza and other acute respiratory viral infections in the course of standard therapy in 3-6 years old patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with clinically diagnosed influenza or other ARVI based on the body temperature > 37,5 ° C, not less than 1 of the following other symptoms of intoxication and not less than 1 of the following of catarrhal symptoms:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ingavirin (Imidazolyl ethanamide pentandioic acid), capsules 30 mg daily for 5 days. The contents of one capsule of Ingavirin, capsules 30 mg should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.
Drug: Imidazolyl ethanamide pentandioic acid
Placebo, capsules daily for 5 days. The contents of one capsule of placebo should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.
Drug: placebo
Also known as: Ingavirin
Time to decrease in the Influenza and Other ARVI Severity Scale score to 2 points with no more than 1 point at individual subscales and normalization of body temperature
Temperature normalization means establishment of body temperature below 37 ° C without raising thereafter till 5 days after the treatment start.
Time frame: 5 days
Time to decrease in the Influenza and Other ARVI Severity Scale score to 0 points
Time frame: 5 days
Average score at the Influenza and Other ARVI Severity Scale by the 1st, 2nd, 3rd, 4th and 5th days after the start of treatment
Time frame: Within 6 days from the start of treatment
The area under the "Influenza and Other ARVI Severity Scale score - time" curve by the 5th day after the start of treatment
Time frame: 5 days
Time to normalization of body temperature from the start of treatment, measured in hours
Temperature normalization means establishment of body temperature below 37°C without raising thereafter till 5 days after the treatment start
Time frame: 5 days
The average body temperature by the1st, 2nd, 3rd, 4th and 5th days after the start of treatment
Time frame: 5 days
The percentage of patients with normalization of body temperature by the 1st, 2nd, 3rd, 4th and 5th days after the start of treatment
Time frame: 5 days
The area under the "temperature-time" curve by the 5th day after the start of treatment
Time frame: 5 days
The percentage of patients with complications of influenza and other ARVI developed over the period from the 1st to the 6th and from the 1st to 14th day after the start of treatment
Time frame: 14 days
The percentage of patients with severe complications of influenza and other ARVI that have developed over the period from the 1st to the 6th and from the 1st to 14th day after the start of treatment
Time frame: 14 days
Time to onset of complications of influenza and other ARVI from the start of treatment
Time frame: 14 days
Assessment of adverse events (AEs) and serious adverse events (SAEs)
Assessment of adverse events (AEs) and serious adverse events (SAEs) by means of - * Portion of patients who developed one or more SAE during the study * Portion of patients who developed one or more AE during the study * Portion of patients who developed one or more severe AE during the study * Portion of patients who developed one or more AE with definite relationship to the investigational product/ placebo during the study * Portion of patients who developed one or more AE with definite or probable relationship to the investigational product/ placebo during the study
Time frame: 14 days
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jan 2016, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pentanedioic acid imidazolyl ethanamide